Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Vemurafenib in patients with Melanoma.

Statements

Source and description
Zelboraf (vemurafenib) [product monograph]. HC. Health Canada approved vemurafenib as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.
Zelboraf (vemurafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.